SCHEMBL6714740

SCHEMBL6714740

COc1cccc(N)c1OP(=O)(OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
RXRA P19793 1/20 0.42
BCHE P06276 3/20 0.41
HTR1A P08908 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
ADRA2B P18089 1/20 0.41
PTGS1 P23219 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 1/20 0.41
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21122038 0.82 NPC1 (0.55) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL7293001 0.78 BCHE (0.58) ALDH1A1KDM4EMAPTBCHEHTR1A
SCHEMBL368084 0.73 TSHR (0.44) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL991032 0.70 TSHR (0.59) NPC1RAB9AALDH1A1TSHR
SCHEMBL6423059 0.70 TSHR (0.59) NPC1RAB9AALDH1A1TSHR
SCHEMBL22905946 0.70 CA12 (0.58) NPC1RAB9AALDH1A1MAPTRXRA
SCHEMBL20472387 0.70 CA12 (0.58) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL8412292 0.70 TSHR (0.50) NPC1RAB9AKMT2ATDP1TSHR
SCHEMBL206609 0.70 TSHR (0.68) NPC1RAB9AALDH1A1TSHR
SCHEMBL17359431 0.70 TSHR (0.53) NPC1RAB9AALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180917-A1 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same HUSSON HENRI-PHILIPPE (FR) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180917-A1 Novel tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing the same SCN11A, CYP4A11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 NPC1 706/4885RAB9A 182/4885MEN1 4058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.